Codexis, Inc. (CDXS)
Company Description
Codexis, Inc. discovers, develops, and sells enzymes and other proteins.
The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services.
The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.
The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency.
The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe.
The company was incorporated in 2002 and is headquartered in Redwood City, California.
Country | United States |
Founded | 2002 |
IPO Date | Apr 22, 2010 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 174 |
CEO | Dr. Stephen George Dilly MBBS, Ph.D. |
Contact Details
Address: 200 Penobscot Drive Redwood City, California 94063 United States | |
Phone | 650-421-8100 |
Website | codexis.com |
Stock Details
Ticker Symbol | CDXS |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001200375 |
CUSIP Number | 192005106 |
ISIN Number | US1920051067 |
Employer ID | 71-0872999 |
SIC Code | 2860 |
Key Executives
Name | Position |
---|---|
Dr. Stephen George Dilly MBBS, Ph.D. | President, Chief Executive Officer and Director |
Kevin Norrett M.B.A., M.S. | Chief Operating Officer |
Margaret Fitzgerald J.D. | Chief Legal and Compliance Officer, General Counsel and Secretary |
Sriram Ryali M.B.A. | Chief Financial Officer |
Carrie McKim | Director of Investor Relations |
Karen Frechou-Armijo | Senior Vice President and Head of Human Resources |
Dr. Stefan Lutz Ph.D. | Senior Vice President of Research |
Robert Sato M.B.A., Ph.D. | Senior Vice President of Pharmaceutical Development, Quality and Regulatory |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 6, 2024 | 8-K | Current Report |
Feb 28, 2024 | 10-K | Annual Report |
Feb 28, 2024 | 8-K | Current Report |
Feb 16, 2024 | 8-K | Current Report |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 13, 2024 | 8-K | Current Report |
Feb 9, 2024 | 8-K | Current Report |
Feb 9, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Jan 24, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |